FDA Person
Office of the CommissionerRoger F. Zabinski
View detailed information about Roger F. Zabinski, including compliance records, violations, and related data.
Person Profile
Comprehensive profile of Roger F. Zabinski, including their role, qualifications, and regulatory activities.
Recent Records (24)
Page 1 of 2483 - JD & SN Inc.
483
483 - Chastains Inc. dba Owl Tri State Pharmacy
483
483 - La Vita Compounding Pharmacy, LLC
483
483 - Algunas Inc., dba Woodland Hills Compounding Pharmacy
483
483 - Algunas Inc., dba Woodland Hills Compounding Pharmacy
483
483 - Ionia Pharmacy
483
483 - Central Admixture Pharmacy Services, Inc.
483
483 - Gland Pharma Limited, Units I+II Pashamylaram Site
483
483 - ImprimisRx CA, Inc., dba ImprimisRx
483
483 - Avella of Deer Valley dba Avella Specialty Pharmacy
483
483 - UCB Pharma S.A.
483
483 - ImprimisRx CA, Inc., dba ImprimisRx
483
483 - Gussyup LLC (dba Private Label Grooming)
483
483 - Pfizer Manufacturing Austria GmbH
483
483 - Poulsbo Compounding Pharmacy LLC, dba Cascade Specialty Pharmacy
483
EIR - Amgen, Inc.
EIR
483 - Pfizer Manufacturing Austria GmbH
483
EIR - UCB Pharma S.A.
EIR
483 - Pfizer Manufacturing Austria GmbH
483
483 - Octapharma S.A.S.
483
Showing 1-20 of 24 records
Related People (5)
Related Office
Person Information
Name
Roger F. Zabinski
Title
Investigator
Role
Regulatory Personnel
ID: 87e05838-f8b5-489a-8db7-6669e68a2c2e
Get More Insights
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
1.5M+ regulatory data points
Real-time compliance monitoring
Interactive analytics dashboard
Looking for more people? Our platform provides access to thousands of FDA people with advanced search and filtering capabilities.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox